期刊
CURRENT OPINION IN PHARMACOLOGY
卷 8, 期 3, 页码 255-260出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2008.03.003
关键词
-
资金
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066554, P50HL084946] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016285] Funding Source: NIH RePORTER
- NHLBI NIH HHS [P50 HL084946-019001, R01 HL066554-09, P50 HL084946, R01HL66554, R01 HL066554, P150 HL 084946-01] Funding Source: Medline
- NIEHS NIH HHS [R01 ES016285] Funding Source: Medline
The discovery of vascular endothelial growth factor (VEGF) changed the field of angiogenesis. We have learned that VEGF has broader actions than merely a driver of tumor angiogenesis, particularly that VEGF controlled several fundamental functions and properties of endothelial cells and nonendothelial cells. The lung is one of the main organs where VEGF controls several crucial physiological functions. These actions rely on tightly regulated temporal and concentration gradients of VEGF and VEGF receptor expression in the lung. Excessive or diminished VEGF have been linked to abnormal lung phenotypes and, in humans, linked to several diseases. The beneficial and detrimental actions of VEGF underscore that therapeutic targeting of VEGF in disease has to carefully consider the lung biology of VEGF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据